Frontier Biotechnologies Inc. (SHA:688221)
China · Delayed Price · Currency is CNY 13.17
-0.45 (-3.30%)
At close: Nov 13, 2026
Frontier Biotechnologies Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 356.68 | 122.23 | 125.76 | 110.42 | 83.4 | 40.47 |
Other Revenue | 1.15 | 1.15 | 3.71 | 3.83 | 1.34 | 0.03 |
| 357.83 | 123.39 | 129.47 | 114.25 | 84.74 | 40.5 | |
Revenue Growth | 153.42% | -4.70% | 13.33% | 34.82% | 109.22% | -13.13% |
Cost of Revenue | 94.02 | 85.27 | 95.63 | 81.13 | 69.35 | 49.71 |
Gross Profit | 263.81 | 38.12 | 33.84 | 33.12 | 15.39 | -9.21 |
Selling, General & Admin | 145.6 | 151.76 | 171.16 | 159.52 | 135.04 | 136.81 |
Research & Development | 161.72 | 141.54 | 137.21 | 214.23 | 274.33 | 172.11 |
Other Operating Expenses | 11.56 | 3.01 | 4.6 | 3.17 | 2.98 | 1.98 |
Operating Expenses | 317.9 | 298.12 | 310.75 | 377.34 | 413.94 | 312.12 |
Operating Income | -54.09 | -260 | -276.9 | -344.22 | -398.56 | -321.33 |
Interest Expense | -2.3 | -9.12 | -10.36 | -8.47 | -4.75 | -1.53 |
Interest & Investment Income | 13.9 | 10.09 | 88.21 | 23.51 | 25.9 | 44.3 |
Currency Exchange Gain (Loss) | -0.06 | -0.06 | 0.15 | -3.58 | 0.68 | 0.09 |
Other Non Operating Income (Expenses) | -22.47 | -21.29 | -3.05 | -0.91 | -2.03 | -0.48 |
EBT Excluding Unusual Items | -65.01 | -280.37 | -201.95 | -333.66 | -378.75 | -278.96 |
Gain (Loss) on Sale of Investments | 8.67 | -1.61 | 0.08 | -1.06 | -0.25 | 0.72 |
Gain (Loss) on Sale of Assets | 0.7 | -0.03 | -0.03 | -3.08 | -0.01 | 0 |
Asset Writedown | -1.32 | - | -36.65 | -3.22 | - | - |
Other Unusual Items | 21.15 | 13.96 | 37.16 | 12.05 | 22.25 | 12.97 |
Pretax Income | -35.81 | -268.05 | -201.38 | -328.96 | -356.76 | -265.27 |
Earnings From Continuing Operations | -35.81 | -268.05 | -201.38 | -328.96 | -356.76 | -265.27 |
Minority Interest in Earnings | - | - | - | - | - | 5.21 |
Net Income | -35.81 | -268.05 | -201.38 | -328.96 | -356.76 | -260.06 |
Net Income to Common | -35.81 | -268.05 | -201.38 | -328.96 | -356.76 | -260.06 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 379 | 372 | 373 | 374 | 364 | 361 |
Shares Outstanding (Diluted) | 379 | 372 | 373 | 374 | 364 | 361 |
Shares Change | 1.84% | -0.17% | -0.24% | 2.69% | 0.79% | 25.23% |
EPS (Basic) | -0.09 | -0.72 | -0.54 | -0.88 | -0.98 | -0.72 |
EPS (Diluted) | -0.09 | -0.72 | -0.54 | -0.88 | -0.98 | -0.72 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 40.63 | -256.45 | -191.12 | -396.52 | -429.42 | -570.22 |
Free Cash Flow Per Share | 0.11 | -0.69 | -0.51 | -1.06 | -1.18 | -1.58 |
Gross Margin | 73.72% | 30.89% | 26.14% | 28.99% | 18.16% | -22.74% |
Operating Margin | -15.12% | -210.72% | -213.87% | -301.28% | -470.32% | -793.34% |
Profit Margin | -10.01% | -217.25% | -155.54% | -287.94% | -421.01% | -642.07% |
Free Cash Flow Margin | 11.36% | -207.85% | -147.61% | -347.07% | -506.74% | -1407.84% |
EBITDA | -43.05 | -236.64 | -237.13 | -301.34 | -352.29 | -283.37 |
EBITDA Margin | -12.03% | -191.79% | -183.15% | -263.76% | - | - |
D&A For EBITDA | 11.03 | 23.35 | 39.78 | 42.88 | 46.27 | 37.96 |
EBIT | -54.09 | -260 | -276.9 | -344.22 | -398.56 | -321.33 |
EBIT Margin | -15.12% | -210.72% | -213.87% | - | - | - |
Revenue as Reported | 20.01 | 123.39 | 129.47 | 114.25 | 84.74 | 40.5 |
Advertising Expenses | - | 8.29 | 0.52 | 0.31 | 0.09 | 1.13 |